Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application.

Tumors have evolved in various mechanisms to evade the immune system, hindering the antitumor immune response and facilitating tumor progression. Immunotherapy has become a potential treatment strategy specific to different cancer types by utilizing multifarious molecular mechanisms to enhance the immune response against tumors. Among these mechanisms, the ubiquitin-proteasome system (UPS) is a significant non-lysosomal pathway specific to protein degradation, regulated by deubiquitinating enzymes (DUBs) that counterbalance ubiquitin signaling. Ubiquitin-specific proteases (USPs), the largest DUB family with the strongest variety, play critical roles in modulating immune cell function, regulating immune response, and participating in antigen processing and presentation during tumor progression. According to recent studies, the expressions of some USP family members in tumor cells are involved in tumor immune escape and immune microenvironment. This review explores the potential of targeting USPs as a new approach for cancer immunotherapy, highlighting recent basic and preclinical studies investigating the applications of USP inhibitors. By providing insights into the structure and function of USPs in cancer immunity, this review aims at assisting in developing new therapeutic approaches for enhancing the immunotherapy efficacy. © 2023. Italian National Cancer Institute ‘Regina Elena’.

Citation

Hongli Gao, Jianqiao Yin, Ce Ji, Xiaopeng Yu, Jinqi Xue, Xin Guan, Shuang Zhang, Xun Liu, Fei Xing. Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application. Journal of experimental & clinical cancer research : CR. 2023 Sep 01;42(1):225

Mesh Tags

Substances

PMID: 37658402

search → result